Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer
Year: 2026
Type: editorial
Abstract: ) received approval for HR-positive and HER2-negative, locally advanced or metastatic breast cancer after detecting ESR1 mutation during medication with aromatase and CDK4/6 inhibitors. The mutation was identified through circulating tumor deoxyribonucleic acid, thus representing its first interventional use to guide a therapy switch as part of a clinical study. Camizestrant is a selective estrogen receptor degrader (SERD) and complete antagonist of the estrogen receptor. A dose of 75 mg is taken by mouth once daily concomitantly with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. In a drug regimen comprising an aromatase inhibitor along with a CDK4/6 inhibitor, a significant improvement in progression-free survival was achieved when the aromatase inhibitor was exchanged for camizestrant. This makes camizestrant a next-generation oral SERD for treating advanced breast cancer. The image identifies three chemical groups within the camizestrant molecule and associates each with a specific functional role: one group controls the degradation profile, another regulates basicity and lipophilicity, and a third influences solubility and protein binding. Additionally, the image includes a pink ribbon labeled with the breast cancer classifications ESR1, HR-positive, and HER2-negative.
Source: Medicinal Chemistry Research
Author: Daniel Baecker
Institution: Freie Universität Berlin
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,990
Funder: Freie Universität Berlin
OpenAlex ID: W7225125660
